Navigation Links
Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels
Date:9/15/2008

ROCKVILLE, Md., Sept. 15 /PRNewswire-USNewswire/ -- Pre-mixed insulin analogues, a modified form of conventional pre-mixed human insulin, are more effective than long-acting analogues for controlling high blood sugar levels after meals in patients with type 2 diabetes, according to a report funded by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.

Conventional pre-mixed human insulin, however, appears to be equally effective as pre-mixed insulin analogues for lowering blood sugar levels when patients go eight or more hours without eating, according to the report. A version of the analysis is available on-line in the Annals of Internal Medicine.

Type 2 diabetes accounts for more than 90 percent of diabetes. The number of Americans diagnosed with type 2 diabetes tripled from 5.6 million in 1980 to 15.8 million in 2005. Obesity increases the risks of developing type 2 diabetes. Diabetes can cause serious problems with the heart, kidneys, eyes and nerves. Many patients with type 2 diabetes control their blood sugar through diet and use of oral medications. Recent research suggests that good blood glucose control can reduce loss of sight, kidney failure, and heart disease.

The new report was compiled by the Johns Hopkins University Evidence-based Practice Center in Baltimore, one of 14 such centers that are funded by AHRQ through its Effective Health Care program. The report represents a systematic review of 45 research studies and is intended to provide unbiased, evidence-based information so that patients, clinicians and others can make the best possible treatment decisions.

"While it is clear that pre-mixed insulin analogues offer certain advantages to patients with diabetes, what is good for one patient may not be good for another," said AHRQ Director Carolyn M. Clancy, M.D. "This report offers an important reminder that patients with diabetes should review their treatment plans carefully with their physician."

Pre-mixed insulin analogues are a modified form of conventional pre-mixed human insulin. AHRQ's report compared pre-mixed insulin analogues with conventional pre-mixed human insulin, oral diabetes drugs, and two other kinds of insulin analogues -- long-acting (or "basal") analogues, and rapid-acting (or "bolus") analogues.

Although non-insulin oral medications are used as a first-line treatment for patients with type 2 diabetes, insulin is frequently required at some stage during the course of the disease. Under such circumstances, some patients are controlled with long-acting insulin alone while others need a combination of long-acting and rapid-acting insulins to control blood sugar levels after meals, especially meals with high sugar content.

About 28 percent use some form of insulin to control blood sugar levels and limit complication risks from type 2 diabetes. Pre-mixed insulin analogues, approved in the U.S. in 2003, are produced by genetically modifying selected proteins of human insulin. Insulin analogues were developed as an alternative to conventional pre-mixed human insulin to provide tighter control of blood sugar levels.

Additional findings in AHRQ's new report:

-- Long-acting insulin analogues appear to be more effective than pre-mixed insulin analogues in lowering fasting blood sugar levels.

-- Pre-mixed insulin analogues are better than long-acting analogues alone in lowering blood sugar levels after a meal with high sugar content.

-- Pre-mixed insulin analogues are more effective than long-acting analogues in lowering Hemoglobin A1c, which is a highly reliable indicator of chronic high blood sugar.

-- Pre-mixed insulin analogues are more effective than non-insulin antidiabetic medications in lowering fasting blood sugar levels.

-- Pre-mixed insulin analogues are more likely than long-acting analogues to be associated with hypoglycemia (blood sugar so low that it can cause symptoms such as fainting), and are similar to pre-mixed human insulin preparations in terms of the frequency of hypoglycemia reported.

-- Pre-mixed insulin analogues are associated with a higher frequency of hypoglycemic events than oral antidiabetic (non-insulin) agents are.

The report, Comparative Effectiveness, Safety and Indications of Pre-mixed Insulin Analogues for Adults With Type 2 Diabetes, is available at effectivehealthcare.ahrq.gov. It is the newest analysis from AHRQ's Effective Health Care Program, authorized by Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. That program supports important federal efforts to comparing alternative treatments for health conditions while making the findings public. The program is intended to help patients, doctors, nurses, and others choose the most effective treatments.


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
2. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
5. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
6. New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Treatment Corrects Severe Insulin Imbalance in Animal Studies
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
11. Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
(Date:2/23/2017)... ... 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti ... Indiegogo campaign . Individuals are now able to contribute to the local initiative, ... as a participating patient or through an Indiegogo donation. The entirety of proceeds will ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Carlos Gutierrez ... He has also continued to spiritually evolve, which is the purpose of everyone in ... Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers to expand ...
(Date:2/22/2017)... Tampa, Fla. (PRWEB) , ... February 22, 2017 ... ... the field of regenerative medicine in recent years. The technology is so cutting ... sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes ...
(Date:2/22/2017)... ... February 22, 2017 , ... South Bend’s Lunkerville, the ... once again feature Heroes On The Water (HOW), a non-profit organization dedicated to helping ... episode has series host ‘Mike D’ traveling to Lake Denmark, New Jersey, to fish ...
Breaking Medicine News(10 mins):